Research programme: stroke therapy - BioTime/University of California Los Angeles

Drug Profile

Research programme: stroke therapy - BioTime/University of California Los Angeles

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator BioTime; University of California at Los Angeles
  • Class Growth factors; Nerve growth factors
  • Mechanism of Action Brain-derived neurotrophic factor expression stimulants; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Stroke

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Stroke in USA
  • 26 Jan 2015 BioTime receives patent allowance for its Pluripotent Stem cells in Singapore
  • 19 Apr 2013 BioTime licenses technology from UCLA to develop therapy for Stroke
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top